When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Table 1 Patient at his first assessment at our asthma clinic

Demographic characteristics
Age (years) Gender BMI Profession	63 Male 28 kg/m² Hairdresser
Airway and blood inflammatory markers
FeNO Sputum eosinophil count Blood eosinophil count Total IgE	63 ppb 8% 239/μl 1510 kU/l
Patient-reported outcomes Quality of life Control of his asthma
ACT ACQ AQLQ	8 4.29 3.07
Respiratory function assessment
VEMS pre-bronchodilation VEMS post-bronchodilation VEMS/CVF % of reversibility with salbutamol PC 20 Methacholine	67% of predicted values 73% of predicted values 76% 6% 0.17 mg/ml
Comorbidity
Nasal polyposis
Atopic status
Dpt Grass Cat Dog Birch	2.6 kU/l 3.4 kU/l < 0.35 kU/l 1 kU/l 2.8 kU/l

BMI Body Mass index; FeNO fraction of exhaled nitric oxide; ACT asthma control test; ACQ asthma control questionnaire; AQLQ asthma quality of life questionnaire

ISSN: 1752-1947